Kiniksa Pharmaceuticals International (KNSA) Revenue (2021 - 2026)

Kiniksa Pharmaceuticals International has reported Revenue for 6 years, with the latest figure at $214.3 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 55.51% year-over-year to $214.3 million; the trailing twelve-month figure through Mar 2026 stood at $754.0 million (up 56.71% YoY), and the FY2025 full-year result was $677.6 million, up 60.09% from the prior year.
• Revenue for Q1 2026 stood at $214.3 million, up from $202.1 million in the prior quarter.
• The five-year high for Revenue was $214.3 million in Q1 2026, with the low at -$148.3 million in Q4 2022.
• Historically, Revenue has averaged $93.8 million across 5 years, with a median of $99.1 million in 2022.
• The largest YoY upside for Revenue was 719.64% in 2022 against a maximum downside of 891.12% in 2022.
• Kiniksa Pharmaceuticals International's Revenue stood at -$148.3 million in 2022, then surged by 156.24% to $83.4 million in 2023, then jumped by 46.93% to $122.5 million in 2024, then surged by 64.95% to $202.1 million in 2025, then advanced by 6.01% to $214.3 million in 2026.
• The last three Revenue figures came in at $214.3 million (Q1 2026), $202.1 million (Q4 2025), and $180.9 million (Q3 2025), per Business Quant data.